Harness attends RNA Leaders USA Congress

This week, our CEO Jan Thirkettle is attending the RNA Leaders USA Congress in Boston, MA, 10-11 September.

At the heart of Harness' innovation is our proprietary MISBA™, platform, which leverages antisense oligonucleotides for finely controlled protein modulation to treat neurodegenerative diseases. If you're attending RNA Leaders, why not connect with Jan to learn more about how we are advancing the field of RNA therapeutics?

#RNALeaders #HarnessTherapeutics #Biotech #Innovation #NeurodegenerativeDiseases

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

January 2025

Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline

September 2024

Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director

View all